EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50

Paul Zarogoulidis; Panos Chinelis; Christofors Efthymiou; Anastasia Athanasiadou; Vasilis Mpikos; George Papatsibas; Vasilis Papadopoulos; Elena Maragouli; Haidong Huang; Georgia Trakada; Anastasios Kallianos; Lemonia Veletza; Wolfgang Hohenforst-Schmidt

doi:10.1016/j.rmcr.2017.05.010

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50

Respir Med Case Rep. 2017 May 30:22:7-10. doi: 10.1016/j.rmcr.2017.05.010. eCollection 2017.

Affiliations

¹ Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Oncology Department, University General Hospital of Larissa, Larissa, Greece.
³ Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
⁴ Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
⁵ Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.

Abstract

Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.

Keywords: Adenocarcinoma; Anaplastic lymphoma kinase; Epidermal growth factor; NSCLC; Programmed death-ligand 1.

Publication types

Case Reports